News

Metastatic Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...
CURE5h
Optune Lua Receives CE Mark in Europe for Metastatic NSCLC
Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.
Taiwan News6h
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media. * Dr.
CURE10h
Ivonescimab Plus Chemo May Slow Advanced NSCLC Progression
CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...
Medscape12h
Less Is More: The Case for De-escalation Strategies in Lung Cancer Management
Oncology experts discuss de-escalation strategies that can reduce toxicity, save a billion in healthcare costs, and make lung ...
Endpoints News15h
Sum­mit, Ake­so re­port an­oth­er Phase 3 win for PD-1xVEGF ap­proach in lung can­cer
Summit Therapeutics and Akeso said their PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a ...
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply.